Iron is essential to life. It transports oxygen, participates in DNA synthesis, and fuels the mitochondrial respiratory chain. But iron has a property that the body manages with difficulty: there is no active excretion mechanism. Daily losses (skin desquamation, trace digestive losses) amount to roughly one milligram per day. The rest accumulates. And this accumulation, long considered benign outside of haemochromatosis cases, is proving to be a silent accelerator of biological aging.
A standard blood donation removes 450 to 500 mL of whole blood, representing approximately 200 to 250 mg of elemental iron. It is the only non-pharmacological intervention capable of effectively reducing the body's iron stores. Data accumulated over thirty years suggest that this periodic depletion produces biological effects well beyond simple generosity.
The Iron Overload Hypothesis and the Female Paradox
In 1981, Jerome Sullivan formulated the iron overload hypothesis to explain an epidemiological paradox that was then unexplained: why do premenopausal women exhibit markedly lower cardiovascular risk than age-matched men (PubMed). The classical oestrogen explanation did not withstand complete analysis. Sullivan proposed that female protection derived from regular menstrual losses, which maintain iron stores at low levels throughout the fertile period.
The hypothesis was strengthened by a striking clinical observation: after menopause, when menstrual losses cease, women's ferritin gradually rises to reach male levels. Their cardiovascular risk increases in parallel, converging with men's by age 65-70. Hormone replacement therapy does not fully restore this protection. Iron depletion contributes to it.
Serum ferritin is not merely a marker of iron stores. Prospective data from the NHANES cohort (National Health and Nutrition Examination Survey) show that elevated ferritin is independently associated with increased risk of myocardial infarction, stroke, and cardiovascular mortality, even after adjustment for classical risk factors (PubMed).
Haemochromatosis: A Natural Model of Iron Overload
Hereditary haemochromatosis provides an involuntary study model. This genetic condition (C282Y mutation of the HFE gene, frequency of 1 in 200 in Northern European populations) causes excessive intestinal iron absorption. Without intervention, ferritin rises to extreme levels (1,000 to 5,000 ng/mL) and iron deposits in the liver, pancreas, heart, and joints.
The consequences are instructive. Undetected haemochromatosis accelerates hepatic fibrosis, causes secondary diabetes through beta cell destruction, and multiplies cardiomyopathy risk two- to threefold. Tissue aging is visibly accelerated. Homozygous C282Y subjects without phlebotomy show significantly elevated markers of systemic oxidative stress (PubMed).
The crucial point: therapeutic phlebotomy almost entirely normalises prognosis. When haemochromatosis subjects are diagnosed early and regularly phlebotomised, their life expectancy returns to that of the general population. Iron is the causal factor, and its removal is the corrective one. This directly validates the mechanism by which blood donation could exert a protective effect in the general population, on a more modest scale but along the same biological axis.
Amount of elemental iron removed during a standard 450-500 mL blood donation, equivalent to 6 to 8 months of net iron accumulation in an adult male.
Free Iron and Oxidative Stress: The Fenton Reaction at the Heart of Aging
The central mechanism by which iron accelerates aging has a name: the Fenton reaction. Described in 1894, it remains one of the most deleterious processes in human biochemistry. Ferrous iron (Fe²⁺) reacts with hydrogen peroxide (H₂O₂) to generate a hydroxyl radical (OH·), the most destructive reactive oxygen species known.
The hydroxyl radical attacks indiscriminately. It oxidises polyunsaturated fatty acids in cell membranes (lipid peroxidation), fragments DNA strands, and modifies proteins through carbonylation (a chemical alteration that deforms them and renders them non-functional). These damages are not abstract. LDL lipid peroxidation constitutes the initial step of atherosclerosis. Mitochondrial DNA fragmentation degrades cellular energy production. Protein carbonylation alters intracellular signalling.
Iron circulates in plasma bound to transferrin, its transport protein. When transferrin binding capacity is saturated, non-transferrin-bound iron (NTBI) appears in the circulation. This NTBI is redox-active: it can directly participate in chemical reactions that produce free radicals. It catalyses the Fenton reaction within the vascular space, directly damaging the endothelium. Subjects with ferritin above 200 ng/mL show significantly higher levels of NTBI and lipid peroxidation markers (PubMed).
Iron depletion through phlebotomy mechanically reduces the substrate availability for this reaction. Less free iron means fewer hydroxyl radicals, less oxidative damage, and a measurable slowing of the cascade connecting oxidative stress to tissue aging.
Iron, Insulin Resistance, and Metabolic Syndrome
The link between iron overload and metabolic dysregulation is established through several converging mechanisms. Excess iron deposits in the pancreas and directly impairs the function of insulin-producing beta cells. It promotes hepatic lipogenesis and increases glucose production. It amplifies oxidative stress in adipose tissue, sustaining the inflammation that underpins insulin resistance.
Clinical data are concordant. Elevated ferritin is an independent risk factor for type 2 diabetes in prospective meta-analyses. The EPIC-Norfolk study, involving 24,000 subjects followed for eleven years, showed that ferritin in the highest quintile doubled the risk of developing type 2 diabetes (PubMed).
Phlebotomy improves insulin sensitivity. A randomised clinical trial showed that three phlebotomies spaced four weeks apart reduced ferritin by 75%, improved HOMA-IR (insulin resistance index), and lowered the triglyceride-to-HDL ratio in subjects with metabolic syndrome (PubMed). Iron removal was directly correlated with improvement in insulin sensitivity. A finding that places iron status management at the crossroads of metabolic biology and longevity.
Epidemiological Data: Donors Live Longer
The most robust data come from large prospective cohorts. In 1998, a Finnish study of 2,862 men followed for nine years showed that regular blood donors had an 88% lower risk of myocardial infarction compared to non-donors, after adjustment for age, smoking, alcohol consumption, and physical activity (PubMed).
This result remained controversial due to the "healthy donor" bias: blood banks reject individuals in poor health, which could explain donors' better survival. Several subsequent studies attempted to control for this bias.
A 2015 Dutch study of 18,249 regular blood donors used an original approach: comparing frequent donors (more than ten donations) to occasional donors (one to two donations). Both groups share the same initial selection bias. Result: the most frequent donors showed significantly lower all-cause mortality, with a dose-response effect. As the number of donations increased, mortality decreased (PubMed).
Scandinavian cohorts confirm this trend. In Sweden, an analysis of over 1.1 million donors found lower cardiovascular and all-cause mortality among regular donors, an effect that persisted after adjustment for multiple confounders (PubMed). The dose-response relationship between cumulative donations and mortality reduction strengthens the hypothesis of a causal link rather than simple selection bias.
Blood Viscosity and Microcirculation
Blood viscosity is an often-underestimated parameter. It depends primarily on haematocrit (the proportion of red blood cells in blood) and fibrinogen concentration. A high haematocrit increases flow resistance in capillaries. The heart must work harder, blood pressure rises, and perfusion of terminal organs (brain, kidneys, extremities) deteriorates.
Blood donation transiently lowers haematocrit. This effect, lasting two to four weeks, improves blood rheology (how smoothly blood flows) and facilitates microcirculation. The FeAST study (Iron and Atherosclerosis Study), a randomised trial of 1,277 subjects with peripheral arterial disease, showed that phlebotomy significantly reduced blood viscosity and improved tissue perfusion (PubMed).
In this study, subjects randomised to the phlebotomy group (targeting ferritin between 25 and 50 ng/mL) showed 16% lower all-cause mortality, although the primary endpoint (mortality + non-fatal myocardial infarction) did not reach statistical significance. Subgroup analysis revealed a significant benefit in subjects aged 43 to 61, with a 44% reduction in all-cause mortality. Interpretation remains cautious, but the direction of effect is consistent with the broader body of observational data.
Haematopoietic Renewal: Stimulating the Bone Marrow
Blood donation removes approximately 10% of circulating blood volume. This loss triggers an immediate compensatory response. The kidneys detect the transient drop in oxygen partial pressure and increase erythropoietin (EPO) secretion. EPO stimulates erythroid progenitors in the bone marrow. Within two to three weeks, the red blood cell pool is rebuilt.
This forced renewal has an often-overlooked consequence. Circulating red blood cells have a lifespan of approximately 120 days. Over time, the proportion of "aged" red blood cells (rigid, less deformable, less efficient at oxygen transport) increases in circulation. Blood donation accelerates their replacement with young, more flexible, and more performant erythrocytes.
Aged red blood cells become rigid and less deformable. Blood donation accelerates their replacement with young erythrocytes, improving oxygen transport capacity and microcirculation.
Haematopoietic stimulation extends beyond red blood cells alone. Bone marrow contains multipotent haematopoietic stem cells, capable of producing all types of blood cells. Their periodic activation by erythropoietic demand maintains their functional competence. In animal models, regular haematopoietic stimulation preserves clonal diversity of stem cells (the variety of active cell lineages) and delays clonal haematopoiesis of indeterminate potential (CHIP), a phenomenon associated with aging and increased cardiovascular risk (PubMed).
CHIP deserves closer attention. With age, certain bone marrow stem cells acquire spontaneous mutations (often in DNMT3A, TET2, or ASXL1 genes) that give them a multiplication advantage. They progressively colonise the bone marrow, reducing clonal diversity. This phenomenon, detectable in over 10% of individuals above age 70, is associated with a doubling of cardiovascular risk and increased leukaemia risk. Maintaining active, diverse haematopoiesis through periodic bone marrow stimulation could slow this clonal drift. The hypothesis is still young, but biologically coherent.
Optimal Frequency, Precautions, and the Longevity Perspective
Intervals and Ferritin Targets
Blood banks in France allow four donations per year for men and two for women (minimum eight-week interval). These intervals are not arbitrary. They allow complete reconstitution of blood volume (48-72 hours), the red blood cell pool (four to six weeks), and iron stores (eight to twelve weeks).
From a ferritin optimisation perspective, the optimal frequency depends on the starting level. A man with ferritin at 300 ng/mL will require several closely spaced donations to reach a zone of 40 to 80 ng/mL, considered optimal in the longevity literature. A premenopausal woman with ferritin at 30 ng/mL has no benefit from donating blood and risks iron-deficiency anaemia.
Transferrin saturation (TSAT) is an essential complementary parameter. Normal ferritin with TSAT above 45% may indicate early iron overload. Conversely, moderately elevated ferritin with low TSAT may reflect an inflammatory state rather than true iron excess. Joint interpretation of both markers is necessary to avoid inappropriate decisions.
Blood Donation as Hormetic Stress
Beyond iron depletion, blood donation exerts a systemic renewal effect. It forces the body to mobilise its reserves, activate its stem cells, and produce new blood cells. This periodic stimulation mimics, on a smaller scale, the hormetic stress (a moderate stress that strengthens the body) that other longevity interventions (intermittent fasting, cold exposure, high-intensity exercise) exploit. The controlled loss of 10% of blood volume activates repair and regeneration pathways that, without this demand, remain dormant.
The analogy with physical exercise is apt. Muscular effort creates micro-tissue damage, transient inflammation, acute oxidative stress. The adaptive response that follows is what produces the benefit: muscular strengthening, improved cardio-respiratory capacity, upregulation of endogenous antioxidant defences. Blood donation operates on the same principle of hormesis (beneficial stimulation through controlled stress), applied to the haematopoietic compartment.
The convergence of data is remarkable. Sullivan's hypothesis, formulated over forty years ago, now finds confirmation at every level of analysis: biochemical (Fenton reaction), cellular (oxidative damage), tissue-level (atherosclerosis, fibrosis), and epidemiological (reduced mortality among donors). The mechanism is direct, reversible, and accessible to any healthy individual.
Blood donation is not a longevity therapy in the strict sense. It is an altruistic act that, through a documented biological side effect, produces measurable benefits for the donor. The reduction in ferritin, haematopoietic renewal, improved blood viscosity, and enhanced insulin sensitivity constitute a coherent set of effects all pointing in the same direction: a slowing of vascular and metabolic aging. For men and postmenopausal women with elevated ferritin, it is likely one of the simplest, most accessible, and best-documented interventions in the longevity repertoire.
Frequently asked questions
References
- Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1(8233):1293-1294 (PubMed).
- Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803-811 (PubMed).
- de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 1999;159(14):1542-1548 (PubMed).
- Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314(7083):793-794 (PubMed).
- Edgren G, Rostgaard K, Vasan SK, et al. The new Scandinavian Donations and Transfusions database (SCANDAT2): a blood safety resource with added versatility. Transfusion. 2015;55(7):1600-1606 (PubMed).
- Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107-1119 (PubMed).
- Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297(6):603-610 (PubMed).
- Forouhi NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007;50(5):949-956 (PubMed).
- Houschyar KS, Ludtke R, Dobos GJ, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 2012;10:54 (PubMed).
- Edgren G, Reilly M, Engstrand L, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst. 2008;100(8):572-579 (PubMed).
- Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498 (PubMed).
